ZA200407187B - Aryl 5-thio-beta-D-glucopyranoside derivatives andtherapeutic agents for diabetes containing the sa me. - Google Patents

Aryl 5-thio-beta-D-glucopyranoside derivatives andtherapeutic agents for diabetes containing the sa me. Download PDF

Info

Publication number: ZA200407187B
Authority: ZA; South Africa
Prior art keywords: group; alkoxy; alkyl; substituted; halogen atom
Prior art date: 2002-08-09

Application number

ZA200407187A

Other languages

English (en)

Inventor

Masakuzu Sato

Hiroyuki Kakinuma

Hajime Asanuma

Original Assignee

Taisho Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-09

Filing date

2004-09-08

Publication date

2006-02-22

2004-09-08 Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd

2006-02-22 Publication of ZA200407187B publication Critical patent/ZA200407187B/en

Links

125000003118 aryl group Chemical group 0.000 title claims description 16
206010012601 diabetes mellitus Diseases 0.000 title claims description 8
125000000217 alkyl group Chemical group 0.000 claims description 42
125000005843 halogen group Chemical group 0.000 claims description 38
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 31
125000003545 alkoxy group Chemical group 0.000 claims description 27
150000003839 salts Chemical class 0.000 claims description 24
125000002252 acyl group Chemical group 0.000 claims description 22
125000001424 substituent group Chemical group 0.000 claims description 21
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 18
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 17
125000003710 aryl alkyl group Chemical group 0.000 claims description 14
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 14
125000003277 amino group Chemical group 0.000 claims description 12
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
150000001875 compounds Chemical class 0.000 claims description 8
125000000753 cycloalkyl group Chemical group 0.000 claims description 8
125000001072 heteroaryl group Chemical group 0.000 claims description 8
125000000592 heterocycloalkyl group Chemical group 0.000 claims description 8
125000004423 acyloxy group Chemical group 0.000 claims description 7
125000002102 aryl alkyloxo group Chemical group 0.000 claims description 7
125000000000 cycloalkoxy group Chemical group 0.000 claims description 7
239000003814 drug Substances 0.000 claims description 7
125000004442 acylamino group Chemical group 0.000 claims description 6
125000003282 alkyl amino group Chemical group 0.000 claims description 6
125000004414 alkyl thio group Chemical group 0.000 claims description 6
125000001691 aryl alkyl amino group Chemical group 0.000 claims description 6
125000004104 aryloxy group Chemical group 0.000 claims description 6
125000004093 cyano group Chemical group *C#N 0.000 claims description 6
125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 6
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
239000000825 pharmaceutical preparation Substances 0.000 claims description 6
125000000542 sulfonic acid group Chemical group 0.000 claims description 6
125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 5
125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 5
230000000694 effects Effects 0.000 claims description 5
125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
229940124597 therapeutic agent Drugs 0.000 claims description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
108091006299 SLC2A2 Proteins 0.000 claims description 3
230000001419 dependent effect Effects 0.000 claims description 3
229940079593 drug Drugs 0.000 claims description 3
239000011734 sodium Substances 0.000 claims description 3
229910052708 sodium Inorganic materials 0.000 claims description 3
229940123208 Biguanide Drugs 0.000 claims description 2
102000004877 Insulin Human genes 0.000 claims description 2
108090001061 Insulin Proteins 0.000 claims description 2
239000004480 active ingredient Substances 0.000 claims description 2
239000003316 glycosidase inhibitor Substances 0.000 claims description 2
229940125396 insulin Drugs 0.000 claims description 2
239000000556 agonist Substances 0.000 claims 4
125000004429 atom Chemical group 0.000 claims 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
229920000180 alkyd Polymers 0.000 claims 2
150000004677 hydrates Chemical class 0.000 claims 2
229910052739 hydrogen Inorganic materials 0.000 claims 2
239000001257 hydrogen Substances 0.000 claims 2
239000003112 inhibitor Substances 0.000 claims 2
229940123324 Acyltransferase inhibitor Drugs 0.000 claims 1
XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 1
229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 claims 1
108090000790 Enzymes Proteins 0.000 claims 1
102000004190 Enzymes Human genes 0.000 claims 1
229940122069 Glycosidase inhibitor Drugs 0.000 claims 1
229940122355 Insulin sensitizer Drugs 0.000 claims 1
102000000853 LDL receptors Human genes 0.000 claims 1
108010001831 LDL receptors Proteins 0.000 claims 1
101150014691 PPARA gene Proteins 0.000 claims 1
102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 1
108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 1
102000001494 Sterol O-Acyltransferase Human genes 0.000 claims 1
108010054082 Sterol O-acyltransferase Proteins 0.000 claims 1
239000002404 acyltransferase inhibitor Substances 0.000 claims 1
230000001539 anorectic effect Effects 0.000 claims 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
206010061428 decreased appetite Diseases 0.000 claims 1
239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 claims 1
201000010099 disease Diseases 0.000 claims 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
229940125753 fibrate Drugs 0.000 claims 1
238000009472 formulation Methods 0.000 claims 1
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
230000003228 microsomal effect Effects 0.000 claims 1
239000000203 mixture Substances 0.000 claims 1
-1 or a : 20 CC Chemical group 0.000 claims 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
230000000069 prophylactic effect Effects 0.000 claims 1
229940121649 protein inhibitor Drugs 0.000 claims 1
239000012268 protein inhibitor Substances 0.000 claims 1
230000000580 secretagogue effect Effects 0.000 claims 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
230000002218 hypoglycaemic effect Effects 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
IOUVKUPGCMBWBT-QNDFHXLGSA-N phlorizin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-QNDFHXLGSA-N 0.000 description 4
230000030558 renal glucose absorption Effects 0.000 description 4
239000008103 glucose Substances 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
238000000034 method Methods 0.000 description 3
102000005744 Glycoside Hydrolases Human genes 0.000 description 2
108010031186 Glycoside Hydrolases Proteins 0.000 description 2
230000009102 absorption Effects 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000029142 excretion Effects 0.000 description 2
229910052736 halogen Inorganic materials 0.000 description 2
150000002367 halogens Chemical class 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
IJJLRUSZMLMXCN-SLPGGIOYSA-N (2r,3r,4s,5r)-2,3,4,6-tetrahydroxy-5-sulfanylhexanal Chemical class OC[C@@H](S)[C@@H](O)[C@H](O)[C@@H](O)C=O IJJLRUSZMLMXCN-SLPGGIOYSA-N 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
239000004129 EU approved improving agent Substances 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
206010022489 Insulin Resistance Diseases 0.000 description 1
IOUVKUPGCMBWBT-DARKYYSBSA-N Phloridzin Natural products O[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-DARKYYSBSA-N 0.000 description 1
230000002411 adverse Effects 0.000 description 1
150000004283 biguanides Chemical class 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000029087 digestion Effects 0.000 description 1
230000005713 exacerbation Effects 0.000 description 1
150000002303 glucose derivatives Chemical class 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
IOUVKUPGCMBWBT-UHFFFAOYSA-N phloridzosid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-UHFFFAOYSA-N 0.000 description 1
235000019139 phlorizin Nutrition 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
210000000512 proximal kidney tubule Anatomy 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Cardiology (AREA)
Hematology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Oncology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)

ZA200407187A 2002-08-09 2004-09-08 Aryl 5-thio-beta-D-glucopyranoside derivatives andtherapeutic agents for diabetes containing the sa me. ZA200407187B (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2002233015		2002-08-09
JP2003097839		2003-04-01
PCT/JP2003/010159 WO2004014930A1 (ja)	2002-08-09	2003-08-08	選択的なアリール５−チオ−β−Ｄ−アルドヘキソピラノシドの製造法

Publications (1)

Publication Number	Publication Date
ZA200407187B true ZA200407187B (en)	2006-02-22

Family

ID=31719867

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200407187A ZA200407187B (en)	2002-08-09	2004-09-08	Aryl 5-thio-beta-D-glucopyranoside derivatives andtherapeutic agents for diabetes containing the sa me.

Country Status (18)

Country	Link
US (2)	US7414072B2 (zh)
EP (2)	EP1528066A4 (zh)
JP (2)	JP3813160B2 (zh)
KR (2)	KR100588457B1 (zh)
CN (2)	CN100341885C (zh)
AU (2)	AU2003254903B9 (zh)
BR (1)	BR0310006A (zh)
CA (2)	CA2493491A1 (zh)
HR (1)	HRP20040814A2 (zh)
MX (2)	MXPA04009265A (zh)
NO (2)	NO20043733L (zh)
NZ (1)	NZ535229A (zh)
PL (2)	PL375298A1 (zh)
RU (1)	RU2322449C2 (zh)
TW (2)	TWI274055B (zh)
UA (1)	UA77300C2 (zh)
WO (2)	WO2004014931A1 (zh)
ZA (1)	ZA200407187B (zh)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1020944C (zh)	1990-01-30	1993-05-26	阿图尔-费希尔股份公司费希尔厂	紧固件
WO2004043471A1 (ja) *	2002-11-13	2004-05-27	Taisho Pharmaceutical Co., Ltd.	鎮痒剤
WO2004089966A1 (ja) *	2003-04-01	2004-10-21	Taisho Pharmaceutical Co., Ltd.	選択的なヘテロアリール５－チオ－β－Ｄ－アルドヘキソピラノシドの製造法
EA015104B1 (ru)	2003-08-01	2011-06-30	Мицубиси Танабе Фарма Корпорейшн	Новые соединения, обладающие ингибирующей активностью в отношении натрийзависимого транспортера
US8785403B2 (en)	2003-08-01	2014-07-22	Mitsubishi Tanabe Pharma Corporation	Glucopyranoside compound
TW200606129A (en) *	2004-07-26	2006-02-16	Chugai Pharmaceutical Co Ltd	Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
ZA200700755B (en) *	2004-07-26	2009-05-27	Chugai Pharmaceutical Co Ltd	Novel cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes
TW200637839A (en)	2005-01-07	2006-11-01	Taisho Pharmaceutical Co Ltd	1-thio-d-glucitol derivatives
TW200637869A (en)	2005-01-28	2006-11-01	Chugai Pharmaceutical Co Ltd	The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
JP5073948B2 (ja) *	2005-01-31	2012-11-14	田辺三菱製薬株式会社	医薬組成物
TWI365186B (en)	2005-01-31	2012-06-01	Mitsubishi Tanabe Pharma Corp	Indole derivatives
JP2009167104A (ja) *	2006-05-02	2009-07-30	Taisho Pharmaceutical Co Ltd	フェニル５−チオグリコシド化合物
EP1854806A1 (en) *	2006-05-02	2007-11-14	MPG Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Thioglycosides as pharmaceutically active agents
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
EP2019679B1 (en) *	2006-05-23	2018-06-20	Theracos, Inc.	Glucose transport inhibitors and methods of use
BRPI0713058A2 (pt) *	2006-06-29	2012-04-10	Taisho Pharmaceutical Co., Ltd.	composto de 1-tioglucitol de c-fenila
TWI418556B (zh)	2006-07-27	2013-12-11	Mitsubishi Tanabe Pharma Corp	吲哚衍生物
FR2906247B1 (fr) *	2006-09-27	2008-12-26	Fournier S A Sa Lab	Nouveaux derives de 5-thioxylopyranose
TWI499414B (zh)	2006-09-29	2015-09-11	Lexicon Pharmaceuticals Inc	鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ２）的抑制物與其應用方法
MX2009003927A (es) *	2006-10-13	2009-04-23	Chugai Pharmaceutical Co Ltd	Derivado espirocetal de tioglucosa y uso del mismo como un agente terapeutico para la diabetes.
UY30730A1 (es)	2006-12-04	2008-07-03	Mitsubishi Tanabe Pharma Corp	Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
US7666845B2 (en)	2006-12-04	2010-02-23	Janssen Pharmaceutica N.V.	Compounds having inhibitory activity against sodium-dependent glucose transporter
CN101611023A (zh)	2006-12-14	2009-12-23	大正制药株式会社	1－苯基1－硫代－d－山梨醇衍生物
US7795228B2 (en) *	2006-12-28	2010-09-14	Theracos, Inc.	Spiroheterocyclic glycosides and methods of use
WO2008109591A1 (en) *	2007-03-08	2008-09-12	Lexicon Pharmaceuticals, Inc.	Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
US20080064701A1 (en) *	2007-04-24	2008-03-13	Ramesh Sesha	Anti-diabetic combinations
US20070172525A1 (en) *	2007-03-15	2007-07-26	Ramesh Sesha	Anti-diabetic combinations
EP2064222B1 (en) *	2007-04-02	2014-05-07	Theracos, Inc.	Benzylic glycoside derivatives and methods of use
JP5653213B2 (ja) *	2007-07-26	2015-01-14	レクシコンファーマシューティカルズインコーポレイテッド	ナトリウム・グルコース共輸送体２阻害剤の調製に有用な方法及び化合物
BRPI0815708B8 (pt) *	2007-08-23	2021-05-25	Theracos Sub Llc	composto, éster de pró-droga, composição farmacêutica, e, método para tratar uma doença ou condição
CN101801371B (zh)	2007-09-10	2012-11-28	詹森药业有限公司	可用作sglt抑制剂的化合物的制备方法
UA101004C2 (en)	2007-12-13	2013-02-25	Теракос, Инк.	Derivatives of benzylphenylcyclohexane and use thereof
CL2008003653A1 (es)	2008-01-17	2010-03-05	Mitsubishi Tanabe Pharma Corp	Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
US8551524B2 (en) *	2008-03-14	2013-10-08	Iycus, Llc	Anti-diabetic combinations
RU2509773C2 (ru)	2008-07-15	2014-03-20	Теракос, Инк.	Дейтерированные бензилбензольные производные и способы применения
DK2324002T3 (en) *	2008-08-22	2016-12-19	Theracos Sub Llc	Methods of making of sglt2 inhibitors
EP2334687B9 (en) *	2008-08-28	2012-08-08	Pfizer Inc.	Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
US9056850B2 (en)	2008-10-17	2015-06-16	Janssen Pharmaceutica N.V.	Process for the preparation of compounds useful as inhibitors of SGLT
CN102316875A (zh)	2009-02-13	2012-01-11	贝林格尔.英格海姆国际有限公司	用于治疗i型糖尿病、ii型糖尿病、葡萄糖耐量降低或高血糖症的sglt-2抑制剂
US20110009347A1 (en)	2009-07-08	2011-01-13	Yin Liang	Combination therapy for the treatment of diabetes
DK2451797T3 (da)	2009-07-10	2013-06-24	Janssen Pharmaceutica Nv	Fremgangsmåde til krystallisation for 1-(b-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-fluorphenyl)-2- thienylmethyl]benzen
RS55909B1 (sr)	2009-10-14	2017-09-29	Janssen Pharmaceutica Nv	Proces za pripremu jedinjenja koja su korisna kao inhibitori sglt2
KR101426180B1 (ko)	2009-11-02	2014-07-31	화이자 인코포레이티드	디옥사-비시클로［3.2.1］옥탄-2,3,4-트리올 유도체
NZ703128A (en)	2010-05-11	2016-04-29	Janssen Pharmaceutica Nv	Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
WO2011153712A1 (en)	2010-06-12	2011-12-15	Theracos, Inc.	Crystalline form of benzylbenzene sglt2 inhibitor
EP2697218B1 (en)	2011-04-13	2016-05-25	Janssen Pharmaceutica NV	Process for the preparation of compounds useful as inhibitors of sglt2
US9035044B2 (en)	2011-05-09	2015-05-19	Janssen Pharmaceutica Nv	L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
TWI637963B (zh)	2012-03-28	2018-10-11	富士軟片股份有限公司	１－（２－脫氧－２－氟－４－硫－β－Ｄ－阿拉伯呋喃糖基）胞嘧啶之鹽
US9193751B2 (en)	2012-04-10	2015-11-24	Theracos, Inc.	Process for the preparation of benzylbenzene SGLT2 inhibitors
RS58568B1 (sr)	2012-08-13	2019-05-31	Fujifilm Corp	Intermedijer za sintezu 1-(2-deoksi-2-fluoro-4-tio-beta-d-arabinofuranozil) citozina, intermedijer za sintezu tionukleozida, i metode za proizvodnju ovih intermedijera
ES2738493T3 (es)	2013-03-14	2020-01-23	Tolero Pharmaceuticals Inc	Inhibidores de JAK2 y ALK2 y métodos para su uso
US11813275B2 (en)	2013-04-05	2023-11-14	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
HK1213818A1 (zh)	2013-04-05	2016-07-15	勃林格殷格翰国际有限公司	依帕列净的治疗用途
CA2812519A1 (en)	2013-04-05	2014-10-05	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
ES2702174T3 (es)	2013-04-05	2019-02-27	Boehringer Ingelheim Int	Usos terapéuticos de empagliflozina
DK2986304T3 (da)	2013-04-18	2022-04-04	Boehringer Ingelheim Int	Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf.
CN105611920B (zh)	2013-10-12	2021-07-16	泰拉科斯萨普有限责任公司	羟基-二苯甲烷衍生物的制备
JP6175553B2 (ja)	2014-02-18	2017-08-09	富士フイルム株式会社	チオラン骨格型糖化合物の製造方法およびチオラン骨格型糖化合物
JP6204223B2 (ja) *	2014-02-19	2017-09-27	富士フイルム株式会社	チオピラノース化合物等の製造方法
TWI678373B (zh)	2014-10-31	2019-12-01	日商富士軟片股份有限公司	硫代核苷衍生物或其鹽及醫藥組合物
US20170071970A1 (en)	2015-09-15	2017-03-16	Janssen Pharmaceutica Nv	Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
KR102198656B1 (ko)	2016-08-31	2021-01-05	후지필름 가부시키가이샤	항종양제, 항종양 효과 증강제 및 항종양용 키트
CN109922813A (zh)	2016-11-10	2019-06-21	勃林格殷格翰国际有限公司	药物组合物、治疗方法及其用途
TW201932119A (zh)	2018-01-29	2019-08-16	日商富士軟片股份有限公司	膽道癌用抗腫瘤劑和膽道癌的處理方法
US11040038B2 (en)	2018-07-26	2021-06-22	Sumitomo Dainippon Pharma Oncology, Inc.	Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2660313B1 (fr) *	1990-04-02	1992-07-03	Fournier Ind & Sante	Nouveau sulfonyl-phenyl-betha-d-thioxylosides, leur procede de preparation et leur utilisation en therapeutique.
DK0850948T3 (da)	1996-12-26	2002-07-29	Tanabe Seiyaku Co	Propiophenonderivater og fremgangsmåde til fremstilling deraf
JP3055135B2 (ja)	1996-12-26	2000-06-26	田辺製薬株式会社	プロピオフェノン誘導体及びその製法
UA71994C2 (en)	1999-08-31	2005-01-17	Kissei Pharmaceutical	Glucopyranosyloxypyrazole derivatives, a pharmaceutical composition containing these derivatives and intermediate compounds for the preparation thereof
FR2801055B1 (fr) *	1999-11-17	2002-02-08	Fournier Ind & Sante	Derives de beta-d-5-thioxylose, procede de preparation et utilisation en therapeutique
EP1270584B1 (en)	2000-03-17	2005-12-07	Kissei Pharmaceutical Co., Ltd.	Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives
US6683056B2 (en) *	2000-03-30	2004-01-27	Bristol-Myers Squibb Company	O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) *	2000-03-30	2003-04-29	Bristol-Myers Squibb Company	O-glucosylated benzamide SGLT2 inhibitors and method
EP1272584B1 (de)	2000-05-20	2004-03-10	Tesa AG	Verwendung eines hochdichten papierträgers als trägerbahn in einem abdeckmaterial für ein klebeband
EA005994B1 (ru) *	2000-09-29	2005-08-25	Киссеи Фармасьютикал Ко., Лтд.	Производные глюкопиранозилоксибензилбензола и содержащие их лекарственные композиции
JP3915116B2 (ja) *	2000-11-02	2007-05-16	味の素株式会社	新規ピラゾール誘導体及びそれらを含有する糖尿病治療薬
KR100701437B1 (ko) *	2000-12-28	2007-03-30	깃세이 야쿠힌 고교 가부시키가이샤	글루코피라노실옥시피라졸 유도체 및 그 의약 용도
WO2003000712A1 (en)	2001-06-20	2003-01-03	Kissei Pharmaceutical Co., Ltd.	Nitrogenous heterocyclic derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
WO2004089966A1 (ja) *	2003-04-01	2004-10-21	Taisho Pharmaceutical Co., Ltd.	選択的なヘテロアリール５－チオ－β－Ｄ－アルドヘキソピラノシドの製造法
US7439232B2 (en) *	2003-04-01	2008-10-21	Taisho Pharmaceutical Co., Ltd.	Heteroaryl 5-thio-β-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same

2003
- 2003-08-08 BR BR0310006-5A patent/BR0310006A/pt not_active IP Right Cessation
- 2003-08-08 MX MXPA04009265A patent/MXPA04009265A/es active IP Right Grant
- 2003-08-08 JP JP2004527383A patent/JP3813160B2/ja not_active Expired - Fee Related
- 2003-08-08 JP JP2004527382A patent/JPWO2004014930A1/ja not_active Ceased
- 2003-08-08 WO PCT/JP2003/010160 patent/WO2004014931A1/ja not_active Ceased
- 2003-08-08 PL PL03375298A patent/PL375298A1/xx not_active Application Discontinuation
- 2003-08-08 KR KR1020047014192A patent/KR100588457B1/ko not_active Expired - Fee Related
- 2003-08-08 UA UA20041210074A patent/UA77300C2/uk unknown
- 2003-08-08 NZ NZ535229A patent/NZ535229A/en unknown
- 2003-08-08 CN CNB038191423A patent/CN100341885C/zh not_active Expired - Fee Related
- 2003-08-08 RU RU2004135914/04A patent/RU2322449C2/ru not_active IP Right Cessation
- 2003-08-08 CA CA002493491A patent/CA2493491A1/en not_active Abandoned
- 2003-08-08 US US10/518,788 patent/US7414072B2/en not_active Expired - Fee Related
- 2003-08-08 TW TW092121886A patent/TWI274055B/zh not_active IP Right Cessation
- 2003-08-08 MX MXPA05000725A patent/MXPA05000725A/es active IP Right Grant
- 2003-08-08 AU AU2003254903A patent/AU2003254903B9/en not_active Ceased
- 2003-08-08 CA CA002478889A patent/CA2478889A1/en not_active Abandoned
- 2003-08-08 TW TW092121895A patent/TW200409778A/zh unknown
- 2003-08-08 US US10/521,809 patent/US7250522B2/en not_active Expired - Fee Related
- 2003-08-08 EP EP03784623A patent/EP1528066A4/en not_active Withdrawn
- 2003-08-08 PL PL03372865A patent/PL372865A1/xx not_active Application Discontinuation
- 2003-08-08 KR KR1020057002280A patent/KR20050056194A/ko not_active Ceased
- 2003-08-08 CN CNB038056402A patent/CN1312165C/zh not_active Expired - Fee Related
- 2003-08-08 EP EP03784622A patent/EP1541578A1/en not_active Withdrawn
- 2003-08-08 HR HR20040814A patent/HRP20040814A2/hr not_active Application Discontinuation
- 2003-08-08 AU AU2003254904A patent/AU2003254904A1/en not_active Abandoned
- 2003-08-08 WO PCT/JP2003/010159 patent/WO2004014930A1/ja not_active Ceased
2004
- 2004-09-07 NO NO20043733A patent/NO20043733L/no not_active Application Discontinuation
- 2004-09-08 ZA ZA200407187A patent/ZA200407187B/en unknown
2005
- 2005-02-07 NO NO20050650A patent/NO20050650L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
KR20050056194A (ko)	2005-06-14
CN1675233A (zh)	2005-09-28
US20050209309A1 (en)	2005-09-22
MXPA04009265A (es)	2005-01-25
HK1079532A1 (zh)	2006-04-07
JPWO2004014930A1 (ja)	2005-12-02
AU2003254903B2 (en)	2008-07-31
WO2004014931A1 (ja)	2004-02-19
HK1077582A1 (zh)	2006-02-17
JP3813160B2 (ja)	2006-08-23
US7250522B2 (en)	2007-07-31
RU2322449C2 (ru)	2008-04-20
TW200406396A (en)	2004-05-01
CA2478889A1 (en)	2004-02-19
PL372865A1 (en)	2005-08-08
TWI274055B (en)	2007-02-21
EP1541578A1 (en)	2005-06-15
NO20043733L (no)	2004-10-20
CN1312165C (zh)	2007-04-25
CN1639180A (zh)	2005-07-13
CA2493491A1 (en)	2004-02-19
RU2004135914A (ru)	2005-05-10
JPWO2004014931A1 (ja)	2005-12-02
US20050256317A1 (en)	2005-11-17
AU2003254904A1 (en)	2004-02-25
NZ535229A (en)	2006-05-26
MXPA05000725A (es)	2005-04-08
CN100341885C (zh)	2007-10-10
EP1528066A1 (en)	2005-05-04
TW200409778A (en)	2004-06-16
KR100588457B1 (ko)	2006-06-12
AU2003254903A1 (en)	2004-02-25
PL375298A1 (en)	2005-11-28
BR0310006A (pt)	2005-02-15
UA77300C2 (en)	2006-11-15
WO2004014930A1 (ja)	2004-02-19
EP1528066A4 (en)	2007-05-02
NO20050650L (no)	2005-03-04
US7414072B2 (en)	2008-08-19
HRP20040814A2 (en)	2005-06-30
KR20050018642A (ko)	2005-02-23
AU2003254903B9 (en)	2008-08-21

Publication	Publication Date	Title
ZA200407187B (en)	2006-02-22	Aryl 5-thio-beta-D-glucopyranoside derivatives andtherapeutic agents for diabetes containing the sa me.
Hagmann et al.	1986	Identification of the major endogenous leukotriene metabolite in the bile of rats as N-acetyl leukotrience E4
US5866617A (en)	1999-02-02	Formulations and methods of use 2,2'-dithio-bis-esthane sulfonate
US20110077212A1 (en)	2011-03-31	Therapeutic uses of sglt2 inhibitors
CA1302275C (en)	1992-06-02	Enzyme inhibitor
Saari et al.	1984	3-Hydroxy-. alpha.-methyltyrosine progenitors, synthesis and evaluation of some (2-oxo-1, 3-dioxol-4-yl) methyl esters
EP0259990A1 (en)	1988-03-16	Rapid acting combination of sodium sulindac and a base
JPH09216824A (ja)	1997-08-19	クラミジア感染症治療剤
CS247191B2 (en)	1986-12-18	Method of acetylerythromycinstearate preparation
TWI326687B (en)	2010-07-01	Amide prodrug of gemcitabine, compositions and use thereof
KR20020015382A (ko)	2002-02-27	포스페이트 수송 억제제
HU183346B (en)	1984-04-28	Process for preparing new 3,4,5-trihydroxy-piperidine derivatives
AU2007341218B2 (en)	2010-09-09	Isosorbide mononitrate derivatives for the treatment of intestinal disorders
CN1466465A (zh)	2004-01-07	肥胖或脂肪肝的预防或治疗药物
Cynkowska et al.	2005	Novel antiglaucoma prodrugs and codrugs of ethacrynic acid
EP1857442A3 (en)	2008-02-06	Novel antimycobacterial compounds
WO2003086471A3 (en)	2004-04-15	Lyophilized and liquid preparations comprising a polysaccharide derivative of camptothecin
US5728402A (en)	1998-03-17	Controlled release formulation of captopril or a prodrug of captopril
FI68970B (fi)	1985-08-30	Foerfarande foer framstaellning av en ny medicinskt anvaendbarhemin-foerening
JPH0647541B2 (ja)	1994-06-22	医療用途を有する新規なヘミン錯化合物を製造する方法
CS209856B2 (en)	1981-12-31	Method of making the new derivatives of the aminoacids
US5149697A (en)	1992-09-22	Cobalt porphyrin pharmaceutical compositions
JP2766303B2 (ja)	1998-06-18	グリコサミノグリカンで修飾されたスーパーオキシドジスムターゼ及びその製造法
KR102401604B1 (ko)	2022-05-24	데스메틸클로자핀의 새로운 용도
CA1271191A (en)	1990-07-03	Alpha-tocopherol (halo)uridine phosphoric acid diester, salts thereof, and methods for producing the same